|
Compounds
|
M/H/0
|
D/H/0
|
M/H/3
|
D/H/3
|
kw (P)
|
corr coeffs
|
M/H/10
|
D/H/10
|
|---|
|
Tyramine
|
1.1
|
1.1
|
2.8
|
2.8
|
0.0074
|
0.66
|
2.1
|
1.2
|
|
Dopamine
|
-1.5
|
1.0
|
3.0
|
2.8
|
0.0045
|
0.88
|
1.7
|
1.4
|
|
Tetradecanoic acid
|
1.2
|
1.2
|
3.0
|
3.0
|
0.0045
|
0.65
|
3.0
|
1.0
|
|
Glycine
|
1.4
|
-1.3
|
2.8
|
2.1
|
0.0074
|
0.77
|
1.6
|
1.3
|
|
Galacturonic acid
|
1.4
|
1.3
|
3.0
|
3.0
|
0.0045
|
0.88
|
1.8
|
1.5
|
|
Hexadecanoic acid
|
-1.0
|
1.2
|
2.2
|
2.5
|
0.0118
|
0.58
|
2.1
|
1.0
|
|
Acetate
|
-1.4
|
-1.3
|
-3.0
|
-3.0
|
0.0045
|
-0.71
|
-2.6
|
-1.1
|
|
Uridine
|
1.4
|
1.4
|
2.5
|
1.3
|
0.0045
|
0.67
|
1.8
|
1.1
|
|
Oleic acid
|
-1.1
|
-1.1
|
2.2
|
-1.1
|
0.0118
|
0.67
|
1.2
|
1.8
|
|
3-Hydroxyproline
|
-1.1
|
1.0
|
2.0
|
1.6
|
0.0284
|
0.64
|
2.9
|
1.3
|
|
Octadecanoic acid
|
1.3
|
-1.3
|
2.5
|
2.5
|
0.0045
|
0.79
|
1.8
|
1.1
|
|
Noradrenaline
|
-1.4
|
-1.3
|
2.5
|
1.0
|
0.0045
|
0.77
|
2.8
|
1.1
|
|
Alanine
|
1.0
|
1.0
|
2.5
|
2.2
|
0.0045
|
0.67
|
1.5
|
1.0
|
|
Gulonate
|
-1.1
|
1.2
|
1.9
|
1.3
|
0.0424
|
0.53
|
2.8
|
1.4
|
|
4-(3-Hydroxy-phenyl)-butyric acid
|
1.2
|
1.3
|
2.1
|
-1.7
|
0.0424
|
0.86
|
1.1
|
1.1
|
|
2-Monopalmitin
|
-1.3
|
-1.3
|
2.5
|
2.4
|
0.0045
|
0.73
|
1.2
|
1.2
|
|
1-Monoeleoylglycerol
|
1.1
|
1.1
|
-1.9
|
1.6
|
0.2912
|
0.6
|
-1.3
|
-1.3
|
|
Cholesterol
|
1.3
|
1.3
|
2.5
|
2.5
|
0.0045
|
0.62
|
1.7
|
1.0
|
|
Butanoic acid
|
1.1
|
-1.2
|
3.0
|
3.0
|
0.0045
|
0.83
|
1.9
|
1.1
|
|
D-galactose
|
-1.4
|
-1.4
|
-1.8
|
-1.8
|
0.0618
|
-0.6
|
-1.3
|
-1.3
|
|
Stearin
|
-1.0
|
1.2
|
-1.3
|
-1.6
|
0.4649
|
0.52
|
-1.4
|
-1.5
|
|
Eicosanoic acid
|
-1.0
|
1.1
|
1.8
|
1.9
|
0.0618
|
0.85
|
1.4
|
1.1
|
|
Tyrosine
|
1.3
|
-1.0
|
2.8
|
1.2
|
0.0074
|
0.88
|
2.3
|
1.4
|
- Note: The correlation coefficients (corr coeffs) of all compounds were calculated from a cross-validated PLS-DA model (Q2Ycum = 0.899, a satisfactory model using two components) on day 3 between the control group and model group with or without Herba Cistanches treatment. Additionally, the fold changes were tested by the nonparametric Kruskal-Wallis test. Kw (P) denotes the P values of the test. H = control group, M = model group, D = treatment group. For example, H/M/0 represents the relative fold changes (model to control) at the pre-dose state.
